摘要

Objectives: Exosomes are small extracellular vesicles ranging from 50-200 nm in diameter, playing a crucial role in cell communication, tissue repair, and regeneration. In these collective studies an innovative therapy method based on Platelet Rich Plasma (PRP) to induce the release of trillions of vesicles by stressing platelets and other blood cells within PRP. Through a specialized protocol and devices, this method enhances platelet activation, providing a plasma rich in exosomes derived from platelets. This approach finds extensive applications in aesthetic, orthobiological and therapeutic treatments Introduction: This study aims to develop an advanced PRP variant targeted for aesthetic and medical applications. The treatment method delivers effective outcomes in various areas such as skin regeneration, hair loss, spot treatments and joint and connective tissue therapies. Notably, this method is entirely autologous, utilizing exosomes derived from the patient's own platelets. This approach ensures safety by being closed to horizontal gene transfer, thereby eliminating the risk of immune reactions or other complications associated with foreign biological materials. Materials / method: Using the D-MED 600µm (D-MED– TURKEY), specially designed blades were employed to stress the cells, inducing the secretion of trillions of vesicles and promoting platelet activation. The shear stress created by the D-MED blades applied mechanical forces to the platelets, leading to their activation and subsequent exosome production. An Advanced PRX Tube with a unique internal design was used to further facilitate the secretion of trillions of vesicles by cells and the activation of platelets. This tube generated vortices through varying G-forces, continuing the activation process. Results: Laboratory findings confirm that this autologus exosome method achieves 1.52×10^12 particles/mL out of 5 mL in total injectable final milieu (7,6 trillions of vesicles) with an average vesicle size of 128.7 nm. This particle count is significantly higher than that of most exosome products currently available on the market, indicating the superior efficacy of our method. CD63 (%99), CD9 (%99,2), CD41 (%99,2), CD81 (%99,1), CD61 (%97) and CD11b (%0,2), CD14 (%0,1), CD45 (%0). Conclusion: Due to its autologous nature, Exomas poses no risk of allergic reactions post-injection, making it a safe and effective treatment option in aesthetic and medical applications.